Lin’s new chapters

Taiwanese biotech Lin Bioscience Inc. and its wholly owned San Diego subsidiary Lin Bioscience Co. Ltd. are planning sequential listings in Taiwan and the U.S. to fund clinical programs targeting different markets.

Lin has two preclinical oncology programs -- LBS-002, a brain-penetrating microtubule polymerization inhibitor for brain cancer; and LBS-007, a cell division cycle 7-related protein kinase (CDC7) inhibitor for leukemias and solid tumors. ...